T2's COVID-19 molecular test gets FDA nod

By LabPulse.com staff writers

September 2, 2020 -- The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization to T2 Biosystems for its COVID-19 molecular diagnostic test, T2SARS-CoV-2 Panel.

The assay tests for the SARS-CoV-2 virus using nasopharyngeal swab samples and provides results in less than two hours. The panel runs on the company's FDA-cleared and automated T2Dx instrument, which can perform seven tests simultaneously. It demonstrated a sensitivity of 95% and specificity of 100% on both positive and negative patient samples, according to the company.

FDA provides guidance on pooling to boost coronavirus test throughput
The U.S. Food and Drug Administration (FDA) has clarified guidance on the validation of pooled coronavirus testing, in a bid to pave the way for submission...
T2 Biosystems to launch COVID-19 test in the U.S.
T2 Biosystems announced it has completed the validation of its COVID-19 molecular diagnostic test and will distribute it commercially in the U.S.
T2 adds coronavirus test to panels, per health network deal
T2 Biosystems has signed a worldwide licensing agreement for a rapid test developed by New Jersey-based Hackensack Meridian Health for SARS-CoV-2.
T2 Biosystems recruits Chembio's John Sperzel as new CEO
T2 Biosystems has named John Sperzel as its new president and CEO. Sperzel most recently served as president and CEO of infectious disease point-of-care...
T2 Biosystems advances new tests through BARDA funding
T2 Biosystems is accelerating the development of new direct-from-blood tests through a milestone-based funding contract with the U.S. Biomedical Advanced...

Copyright © 2020 LabPulse.com

Last Updated ls 9/21/2020 8:45:42 AM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current